Return On Capital Employed Overview: Boston Scientific

Boston Scientific BSX posted a 124.76% decrease in earnings from Q3. Sales, however, increased by 1.84% over the previous quarter to $2.71 billion. Despite the increase in sales this quarter, the decrease in earnings may suggest Boston Scientific is not utilizing their capital as effectively as possible. Boston Scientific collected $2.66 billion in revenue during Q3, but reported earnings showed a $206.00 million loss.

What Is Return On Capital Employed?

Changes in earnings and sales indicate shifts in Boston Scientific's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q4, Boston Scientific posted an ROCE of 0.0%.

It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

For Boston Scientific, the return on capital employed ratio shows the number of assets can actually help the company achieve higher returns, an important note investors will take into account when gauging the payoff from long-term financing strategies.

Q4 Earnings Recap

Boston Scientific reported Q4 earnings per share at $0.23/share, which did not meet analyst predictions of $0.31/share.